Basic Information
| LncRNA/CircRNA Name | EBIC |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Cisplatin | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | ovarian cancer |
| ICD-0-3 | C56.9 |
| Methods | qPCR, Western blot |
| Sample | ovarian cancer tissues, cell lines (OVCA429, SKOV-3) |
| Expression Pattern | up-regulated |
| Function Description | qRT-PCR showed that lncRNA EIBC was highly expressed in ovarian cancer tissue, compared with adjacent tissue. we found that expression of lncRNA EIBC was closely related to prognosis, tumor size and lymph node metastasis. We also found that the cell proliferation, invasion, migration and cisplatin resistance in ovarian cancer cells after transfection with siRNA-EBIC were significantly inhibited. it indicated that the expression of EBIC was negatively correlated with the survival time of patients with ovarian cancer. |
| Pubmed ID | 30058681 |
| Year | 2018 |
| Title | LncRNA EBIC Promoted Proliferation, Metastasis and Cisplatin Resistance of Ovarian Cancer Cells and Predicted Poor Survival in Ovarian Cancer Patients. |
External Links
| Links for EBIC | GenBank HGNC NONCODE |
| Links for ovarian cancer | OMIM COSMIC |